Physician profile
Susan E Lyons
NPI 1104902063
$3,207.83
in general payments reported to CMS, 2019-2025
39 companies · $729 in 2025
The $729 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $92.22 · 2021: $166 · 2022: $167 · 2023: $163 · 2024: $279 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.63 |
| Education | $134.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $269.50 | 2019-2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $269.26 | 2019-2021 | |
| Sobi, INC | $224.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $215.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $186.65 | 2019-2024 | Calquence, Imfinzi |
| Amgen INC. | $171.09 | 2019-2022 | |
| Abbvie INC. | $155.71 | 2024-2025 | |
| Astellas Pharma US INC | $142.93 | 2019-2024 | Padcev, Xospata |
| Genentech USA, INC. | $138.24 | 2019-2025 | Polivy, Itovebi |
| Merck Sharp & Dohme LLC | $122.82 | 2019-2024 | |
| Janssen Biotech, INC. | $121.92 | 2019-2025 | Rybrevant, Erleada |
| Syndax Pharmaceuticals, INC. | $103.26 | 2025 | |
| Pfizer INC. | $94.93 | 2019-2025 | |
| Celgene Corporation | $91.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.26 | 2019-2025 | Opdivo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $75.17 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $75.12 | 2019 | |
| Lilly USA, LLC | $66.85 | 2019 | |
| Agios Pharmaceuticals, INC. | $63.15 | 2019-2024 | |
| Puma Biotechnology, INC. | $54.52 | 2019-2021 | |
| Incyte Corporation | $53.59 | 2019 | |
| Emd Serono, INC. | $47.08 | 2024 | |
| Boston Scientific Corporation | $36.93 | 2019 | |
| Aveo Pharmaceuticals, INC. | $33.96 | 2025 | |
| Recordati_rare_diseases_inc. | $32.00 | 2025 | Enjaymo |
| Pharmacyclics LLC, An Abbvie Company | $30.70 | 2019 | |
| Gilead Sciences, INC. | $28.24 | 2021-2025 | Trodelvy |
| Genmab U.S., INC. | $28.16 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.33 | 2025 | |
| Tersera Therapeutics LLC | $22.32 | 2025 | Zoladex |
| Blueprint Medicines Corporation | $21.81 | 2025 | Ayvakit |
| Array Biopharma INC | $20.26 | 2019 | |
| G1 Therapeutics, INC. | $16.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.68 | 2025 | Libtayo |
| Mylan Pharmaceuticals INC. | $15.84 | 2019 | |
| Glaxosmithkline, LLC. | $15.24 | 2025 | Ojjaara |
| Verastem, INC. | $13.43 | 2019 | |
| Exelixis INC. | $13.33 | 2019 | |
| Daiichi Sankyo INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.